Rizatriptan (Maxalt®) is a triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).
Maxalt obtained approval by the FDA on June 29, 1998.
Rizatriptan is available only by prescription in the United States and Canada.
This medication is used to treat acute migraine attacks. This drug does not prevent future migraine attacks.